Merck investors can rest easy over the company's sleep aid Belsomra (suvorexant), a first-of-its-kind product, now that the FDA has finally given its blessing to the medicine – with the firm winning approval to market the drug at the 5mg, 10mg, 15mg and 20mg doses.
Merck investors can rest easy over the company's sleep aid Belsomra (suvorexant), a first-of-its-kind product, now that the FDA has finally given its blessing to the medicine – with the firm winning approval to market the drug at the 5mg, 10mg, 15mg and 20mg doses.
Shares of Whitehouse Station, New Jersey-based Merck got a 1
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
